Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Update

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the recipient of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 121,300 shares, a growth of 46.5% from the October 15th total of 82,800 shares. Based on an average daily volume of 145,700 shares, the short-interest ratio is presently 0.8 days. Currently, 4.8% of the company’s stock are sold short.

Hedge Funds Weigh In On Aligos Therapeutics

Several large investors have recently added to or reduced their stakes in ALGS. Acadian Asset Management LLC increased its holdings in Aligos Therapeutics by 17.6% during the 1st quarter. Acadian Asset Management LLC now owns 657,995 shares of the company’s stock worth $644,000 after purchasing an additional 98,628 shares in the last quarter. Opaleye Management Inc. boosted its position in shares of Aligos Therapeutics by 25.7% during the first quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock valued at $1,597,000 after buying an additional 333,000 shares during the last quarter. Finally, Armistice Capital LLC grew its holdings in Aligos Therapeutics by 5.3% during the second quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock worth $2,540,000 after buying an additional 363,000 shares in the last quarter. Institutional investors own 60.43% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $75.00 target price on shares of Aligos Therapeutics in a research report on Thursday, November 7th.

Aligos Therapeutics Stock Up 9.7 %

Shares of NASDAQ:ALGS opened at $19.58 on Thursday. Aligos Therapeutics has a twelve month low of $6.76 and a twelve month high of $30.00. The stock’s 50 day moving average is $9.95 and its 200-day moving average is $12.46. The firm has a market capitalization of $62.66 million, a price-to-earnings ratio of -1.46 and a beta of 2.11.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($3.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.15) by ($0.92). The business had revenue of $1.27 million during the quarter, compared to the consensus estimate of $1.00 million. Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. During the same period last year, the business posted ($10.25) earnings per share. Equities research analysts anticipate that Aligos Therapeutics will post -10.36 earnings per share for the current fiscal year.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).